11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Neurology

Topics

Medicine

Pathology

Physiology

Internal Medicine

Gastroenterology

Show all topics

DOI

10.1016/s1474-4422(10)70043-0